Dyne Therapeutics’ (DYN) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN) in a report released on Monday,Benzinga reports. HC Wainwright currently has a $46.00 price target on the stock.

A number of other research firms also recently issued reports on DYN. BMO Capital Markets started coverage on shares of Dyne Therapeutics in a research report on Wednesday, March 12th. They issued an “outperform” rating and a $50.00 price target on the stock. Baird R W upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Piper Sandler reduced their target price on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. Scotiabank began coverage on shares of Dyne Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $50.00 target price for the company. Finally, Robert W. Baird initiated coverage on shares of Dyne Therapeutics in a research note on Friday, December 13th. They set an “outperform” rating and a $46.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $48.85.

Dyne Therapeutics Price Performance

Shares of DYN stock opened at $12.31 on Monday. The firm has a market cap of $1.39 billion, a P/E ratio of -3.46 and a beta of 1.11. Dyne Therapeutics has a 1-year low of $11.18 and a 1-year high of $47.45. The firm has a fifty day moving average of $14.33 and a two-hundred day moving average of $24.90.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. On average, sell-side analysts expect that Dyne Therapeutics will post -3.44 EPS for the current year.

Insider Buying and Selling

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total value of $36,242.10. Following the sale, the insider now directly owns 199,087 shares in the company, valued at $2,777,263.65. The trade was a 1.29 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold 6,237 shares of company stock worth $77,760 in the last ninety days. 20.77% of the stock is currently owned by corporate insiders.

Institutional Trading of Dyne Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. FMR LLC raised its holdings in shares of Dyne Therapeutics by 69.7% during the third quarter. FMR LLC now owns 9,026,697 shares of the company’s stock valued at $324,239,000 after acquiring an additional 3,707,734 shares during the period. Janus Henderson Group PLC raised its holdings in shares of Dyne Therapeutics by 8.3% during the fourth quarter. Janus Henderson Group PLC now owns 7,379,309 shares of the company’s stock valued at $173,808,000 after acquiring an additional 566,146 shares during the period. RTW Investments LP raised its holdings in shares of Dyne Therapeutics by 6.8% during the third quarter. RTW Investments LP now owns 6,818,641 shares of the company’s stock valued at $244,926,000 after acquiring an additional 431,503 shares during the period. RA Capital Management L.P. raised its holdings in shares of Dyne Therapeutics by 5.5% during the third quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock valued at $229,211,000 after acquiring an additional 331,940 shares during the period. Finally, State Street Corp raised its holdings in shares of Dyne Therapeutics by 13.8% during the third quarter. State Street Corp now owns 3,641,859 shares of the company’s stock valued at $130,816,000 after acquiring an additional 440,890 shares during the period. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.